41
Participants
Start Date
October 31, 2012
Primary Completion Date
March 31, 2013
Study Completion Date
July 31, 2013
Peginesatide
All participants will receive peginesatide for the first 24 weeks.
Epoetin alfa
All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Research Site, Yonkers
Research Site, Amherst
Research Site, Chesapeake
Research Site, Winston-Salem
Research Site, Orangeburg
Research Site, Dyersburg
Research Site, Jackson
Research Site, Kansas City
Research Site, Oklahoma City
Research Site, Houston
Research Site, Meridian
Research Site, Phoenix
Research Site, Tempe
Research Site, Los Angeles
Research Site, Lynwood
Research Site, Whittier
Research Site, Paramount
Research Site, Granada Hills
Research Site, Azusa
Research Site, Riverside
Research Site, Bakersfield
Research Site, Orange
Research Site, Bayonne
Lead Sponsor
Amgen
INDUSTRY